{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:45:18Z","timestamp":1793036718781,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["22\/713\/A"],"award-info":[{"award-number":["22\/713\/A"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09016-0","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:19:53Z","timestamp":1756117193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mate Whenua\u2014follow-up after early medical abortion: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9194-9585","authenticated-orcid":false,"given":"Michelle R.","family":"Wise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jane","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bev","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Parag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh O\u2019Mara","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"9016_CR1","unstructured":"Abortion Legislation Act 2020 https:\/\/www.legislation.govt.nz\/act\/public\/2020\/0006\/latest\/LMS237600.html"},{"key":"9016_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002855.pub5","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD002855.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"9016_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMsa2109779","volume":"386","author":"L Schummers","year":"2022","unstructured":"Schummers L, Darling EK, Dunn S, MacGrail K, Gayowski A, Law MR, et al. Abortion safety and use with normally prescribed mifepristone in Canada. N Engl J Med. 2022;386:57\u201367. https:\/\/doi.org\/10.1056\/NEJMsa2109779.","journal-title":"N Engl J Med"},{"key":"9016_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16668","author":"ARA Aiken","year":"2021","unstructured":"Aiken ARA, Lohr PA, Lord J, Ghosh N, Starling J. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. Br J Obstet Gynaecol. 2021. https:\/\/doi.org\/10.1111\/1471-0528.16668.","journal-title":"Br J Obstet Gynaecol"},{"key":"9016_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.contraception.2021.03.025","volume":"104","author":"C Kerestes","year":"2021","unstructured":"Kerestes C, Murayama S, Tyson J, Natavio M, Seamon E, Raidoo S, et al. Provision of medication abortion in Hawai\u2019i during Covid-19; practical experience with multiple care delivery models. Contraception. 2021;104:49\u201353.","journal-title":"Contraception"},{"key":"9016_CR6","unstructured":"Ministry of Health. 2021. Abortion Services Aotearoa New Zealand: Annual report. Wellington: Ministry of Health. https:\/\/www.health.govt.nz\/publication\/abortion-services-aotearoa-new-zealand-annual-report-2021"},{"key":"9016_CR7","doi-asserted-by":"crossref","unstructured":"Standardizing abortion research outcomes (STAR): Results from an international consensus development study. Contraception\u00a02021;104:484\u201391. https:\/\/www.contraceptionjournal.org\/article\/S0010-7824(21)00224-9\/fulltext","DOI":"10.1016\/j.contraception.2021.07.004"},{"key":"9016_CR8","unstructured":"Ministry of Health. 2021. New Zealand Aotearoa Abortion Clinical Guideline. Wellington: Ministry of Health. https:\/\/www.health.govt.nz\/system\/files\/documents\/publications\/new_zealand_aotearoa_abortion_clinical_guideline.pdf"},{"key":"9016_CR9","unstructured":"Medical Abortion; Clinical Practice Guideline. 2016 J Obstet Gynaecol Can. 2016;38:366\u2013389. https:\/\/www.jogc.com\/article\/S1701-2163(16)00043-8\/fulltext"},{"key":"9016_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.contraception.2011.09.007","volume":"85","author":"EL Horning","year":"2012","unstructured":"Horning EL, Chen BA, Meyn LA, Creinin MD. Comparison of medical abortion follow-up with serum human chorionic gonadotropin testing and in-office assessment. Contraception. 2012;85:402\u20137.","journal-title":"Contraception"},{"key":"9016_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/AOG.0b013e3182839fda","volume":"121","author":"I Dayananda","year":"2013","unstructured":"Dayananda I, Maurer R, Fortin J, et al. Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial. Obstet Gynecol. 2013;121:607\u201313.","journal-title":"Obstet Gynecol"},{"key":"9016_CR12","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/1471-0528.15922","volume":"126","author":"N Baiju","year":"2019","unstructured":"Baiju N, Acharya G, D\u2019Antonio F, Berg RC. Effectiveness, safety and acceptability of self-assessment of the outcome of first-trimester medical abortion: a systematic review and meta-analysis. BJOG. 2019;126:1536\u201344.","journal-title":"BJOG"},{"key":"9016_CR13","unstructured":"The use of mifepristone for medical abortion. Statement C-Gyn 21. 2019. Royal Australian and New Zealand College of Obstetrics and Gynaecology: Melbourne."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09016-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09016-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:50:38Z","timestamp":1757483438000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09016-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9016"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09016-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial received ethics approval through the Health and Disability Ethics Committee (HDEC) New Zealand full review pathway (Northern B Health and Disability Ethics Committee) granted on 15 June 2023 (Reference: 2023 FULL 13189). Protocol amendment was granted on 15 January 2024. Progress reports are provided regularly to HDEC. Written, informed consent to participate will be obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent form given to participants can be provided on request to the PI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AK reports a\u00a0conflict of interest as a director and shareholder of Istar Ltd. (registered charity CC20298). Istar Ltd. imports both Mifegyne (mifepristone) and CheckToP (low sensitivity urine pregnancy test). AK receives a nominal annual director\u2019s fee from Istar Ltd. but does not receive any other dividends from the charity.The remaining investigators declare no conflict of financial or other competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}